The identification of prognostic parameters and surrogate markers for defining patient risk has been beneficial in effectively guiding therapy and increasing the survival of leukemia patients. It has been hypothesized that the therapeutic response, as measured by a change in tumor burden during therapy, might serve as a new surrogate marker of survival. Here we describe the development of a murine SCID xenograft model of human T cell acute lymphoblastic leukemia (T-ALL), and the use of a sensitive, quantitative PCR assay for the measurement of tumor levels to investigate the relationships between tumor burden quantification, therapeutic response and survival. Animals engrafted with the CCRF-CEM (CEM) human T-ALL cell line develop leukemia that closely resembles the human disease. Quantitative PCR detects the expanding tumor mass in the peripheral blood of the animals several weeks before death. In response to induction therapy with chemotherapeutic agents, both the level of minimal residual disease (MRD) in peripheral blood at the end of therapy and the rate of tumor reduction in peripheral blood during therapy strongly correlated with animal survival. Thus, these surrogate markers, which can be measured during the early stages of therapy, may help improve patient survival through dynamic risk stratification. Leukemia (2000) 14, 1215-1224.
Introduction
Great success has been achieved in the treatment of pediatric acute lymphoblastic leukemia (ALL) over the past 50 years. Beginning with Farber's initial discovery of the efficacy of antifolates in 1948, 1 and continuing with the onset of cycling combination chemotherapy regimens and CNS prophylaxis (reviewed in Ref. 2) , the 5-year event-free survival of pediatric patients with acute lymphoblastic leukemia has improved from near 0% to almost 80%. 2, 3 This improvement in therapy has turned research strategies toward the identification of patients at risk for disease relapse.
Risk-directed therapy improves overall survival by calling for aggressive therapy in those patients at high risk of relapse and minimizing toxicity in those at low risk. With the advent of radical, yet effective, therapies such as bone marrow transplantation and/or intensified chemotherapy, there are means of treating high-risk or relapsing patients. 4, 5 The effectiveness of these therapeutic approaches depends on the early identification of patients at high risk of relapse.
Patient risk stratification has evolved in parallel with changes in therapy. Current protocols for the assessment of risk evaluate a combination of clinical, morphologic, cytogenetic, and molecular data. Prognostic parameters at diagnosis for ALL patients include age, white blood cell count (WBC), DNA content, 6 cell-surface markers, and various chromosomal rearrangements (reviewed in Refs 7 and 8). For example, patients with ALL who are over 9 years old, have a WBC Ͼ50 000/l, and carry a t(4;11) (mll/af4 fusion) or t(9;22) (bcr/abl fusion) chromosomal rearrangement have a much poorer prognosis than others. ALL patients who carry disease with a T cell phenotype do poorly overall when compared to patients with pre-B-ALL.
Risk stratification includes not only parameters determined at diagnosis, but also evolving characteristics of the tumor following therapy. Indeed, these surrogate markers for survival may be more informative because they reflect the dynamic nature of an individual disease rather than a statistical probability of relapse at diagnosis. Much of the focus of research in this area has been on the prognostic significance of minimal residual disease (MRD) detection following induction therapy. In the majority of studies, the detection of MRD is an indicator of a poor prognosis (reviewed in Ref. 9 ). These studies have been performed using a variety of detection methods including morphologic detection of blasts in the marrow, immunologic detection using flow cytometry, and molecular detection by Southern blot or PCR. PCR analysis appears to be evolving as the preferred method in some circumstances due to its ease of use and its extreme sensitivity, with some groups documenting a limit of detection of one cell in a background of 10 6 normal cells. 10 Quantitative approaches indicate that the MRD level at specific points throughout therapy is more predictive of relapse than the mere detection of tumor, in certain disease settings. 11, 12 It is possible that the level of tumor, or perhaps the expansion or contraction of the tumor mass, is more indicative of patient response than its presence. Recently, the quantification of fusion transcripts associated with t(8;21) in AML by PCR was evaluated in this regard. 13 It was determined that patients carrying greater than 1.5 × 10 3 fusion transcripts per g RNA following induction/consolidation therapy were at high risk for relapse.
We have recently developed a quantitative PCR assay capable of detecting and accurately quantifying low levels of tumor carrying specific genetic abnormalities.
14 This assay utilizes an internal calibration standard (ICS) that is co-amplified with the tumor-specific genomic DNA target, and therefore corrects for amplification efficiency differences between PCR reactions. Using this type of a quantitative approach (termed ICS-PCR), one can address the significance of MRD detection, MRD levels, and dynamic changes in tumor load throughout therapy in biopsy material or blood.
Murine SCID xenograft models have been described as a means for engrafting human cells as models for evaluating therapy of human malignancies. [15] [16] [17] [18] [19] [20] [21] [22] [23] Here we describe the development of a model in which the human T-ALL cell line CCRF-CEM (CEM) is grown in SCID mice. This cell line causes a reproducible leukemic picture with 100% lethality following intravenous challenge with 10 7 tumor cells. CEM contains a tal-1 d1 deletion, which is a common chromosomal rearrangement found in pediatric T-ALL patients. This tumor-specific molecular marker can be used to detect tumor cells by PCR. In this model, tumor cells could be detected and quantified by ICS-PCR so that disease progression could be monitored by sampling peripheral blood. It is shown that tumor-burden monitoring by ICS-PCR is able to predict disease-free interval in the animals during tumor expansion, a model of relapse. More importantly, the kinetic rate of tumor reduction during therapy, as measured by ICS-PCR, also strongly correlated with disease-free interval. Thus, quantitative tumor-burden analysis by ICS-PCR serves as an early surrogate marker for survival.
Materials and methods

Cell lines
Cell lines used for this study were all human T-ALL lines: CCRF-CEM (CEM), HSB-2, MOLT-16, RPMI 8402 all carry the tal-1 d1 rearrangement; MOLT-3 and MOLT-13 do not. Cell lines were cultured in 0.1-m-filtered RPMI 1640 (RPMI) media with 25 mM HEPES buffer (Gibco BRL, Gaithersburg, MD, USA), supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Gibco BRL), 0.1 mM MEM non-essential amino acids (Gibco BRL), 1 mM MEM sodium pyruvate (Gibco BRL), 2 mM L-glutamine (Gibco BRL), 100 U/ml penicillin G (Gibco BRL), and 100 g/ml streptomycin (Gibco BRL). Cells were grown at 37°C in a 5% CO 2 /air mixture, and were passaged under sterile conditions in a laminar flow hood from a concentration of 2 × 10 6 cells/ml to 10 5 cells/ml every 3 to 4 days.
Animals
For the xenograft model, 5-to 7-week-old female, SCID/Ncr mice (National Cancer Institute, Frederick, MD, USA) were used. Animals were housed under SPF conditions. Sterile food and water was given ad libitum.
Tumor-cell injections and animal monitoring
To prepare tumor cells for injection into animals, cells were washed with 5% FBS in phosphate-buffered saline (PBS), resuspended in 5% FBS in PBS at a concentration of 5 × 10 7 cells/ml (for a 10 7 cell injection) and stored on ice. For both intravenous and intraperitoneal injections, 200 l of the cell suspension was injected. For intravenous injections, animals were heated for 10 to 15 s by a heat lamp to dilate the lateral tail veins.
Following tumor challenge, animals were followed for clinical signs of leukemia development, including lethargy, weight loss, ruffled fur, lack of responsiveness to stimuli, and the presence of visible or palpable masses. Animals either died spontaneously or were sacrificed when moribund. In the CEM xenograft model, animals showing clinical evidence of disease survived an average of 4 days, and therefore, time of death was calculated as the time of clinical disease onset plus 4 days.
Determination of engraftment pattern by PCR and histology
Animals were sacrificed and their organs harvested 14, 21, and 28 days following a 10 7 CEM-cell challenge. Bone marrow, spleen, kidney, liver, lung, heart, thymus, mesenteric lymph nodes, spinal cord, meninges, brain, and tongue were examined by PCR and histology. For PCR analysis, a 10-20 mg portion was removed and homogenized for DNA isolation (see DNA isolation below). For histologic analysis, the remaining portion of the tissue was fixed in 4% paraformaldehyde and decalcified in 100× volume of 5% formic acid in neutral-buffered formalin for 3 days, if necessary. These samples were then immobilized in paraffin blocks, sectioned, and stained with hematoxylin/eosin. 24 
Blood sample collection and processing
Animals were warmed with a heat lamp for 10 to 15 s and bled via the lateral tail vein. For each sample, 10 to 50 l of blood was quantitatively collected with a pipette and placed in a microcentrifuge tube containing 1 ml of 4 mM EDTA in PBS. Samples were stored on ice until processing. Cells were pelleted at 200 g and resuspended with 1 ml of ammonium chloride RBC lysis buffer (0.15 M NH 4 Cl, 1.0 mM KHCO 3 , 0.1 mM Na 2 EDTA, pH 7.3). Following a 7-min incubation on ice, cells were washed twice with 1 ml of 5% FBS in PBS. For the flow cytometric analysis experiments, the samples were resuspended in 400 l of 5% FBS in PBS, and then divided in two: 200 l for DNA isolation and 200 l for both flow cytometry and a WBC count. For the experiments requiring only ICS-PCR analysis, samples were resuspended in 200 l of the 5% FBS in PBS solution.
DNA isolation
DNA was extracted essentially according to the manufacturer's protocol for isolation of DNA from blood or from murine tissue, using the QIAamp Blood and Body Fluid kit (Qiagen, Valencia, CA, USA) or the QIAamp Tissue Kit (Qiagen), respectively. The protocol for isolation from blood had the following modifications. For the final elution step, the isolation columns were incubated with 200 l TE (10 mM Tris/HCl, 1 mM EDTA/NaOH, pH 9.0) at 70°C for 5 min before centrifugation. The columns were eluted twice (the second time with the re-applied eluate) to achieve maximum DNA yield. The DNA samples were then concentrated by EtOH precipitation and resuspended in TE such that 1 l of the final DNA solution was equivalent to 1 l of the original blood sample.
PCR conditions and quantification
PCR was performed as previously described.
14 Primer sequences used for the amplification of the tal-1 d1 rearrangement found in CEM are 5′-CGAGGTTTCTGACCAGTCAG-3′ (5′ primer) and 5′-AGAGCCTGTCGCCAAGAAGAC-3′ (3′ primer). Reactions (50 l) contained 20 pmol of each oligonucleotide primer (Biosource International, Camarillo, CA, USA), in MasterAmp PreMix G buffer (100 mM KCl, 100 mM TrisHCl, pH 8.3, 30 mM MgCl 2 , 400 M of dATP, dGTP, dCTP, and 300 M dTTP, and 6× of the MasterAmp enhancer) (Epicentre Technologies, Madison, WI, USA), with 2.5 units of Taq polymerase (Perkin-Elmer, Branchburg, NJ, USA), and template DNA as indicated. Amplification conditions consisted of a 95°C initial denaturation step for 5 min, then 34 cycles of 95°C for 0.5 min, 60°C for 0.5 min, and 72°C for 1 min, and then a 9 min 72°C final extension. Reactions were processed in a Perkin-Elmer 9600 or 2400 thermocycler.
In the quantitative assay, the LQ1 ICS is included in each reaction.
14 The ICS contains primer sequences from the flanking regions of several common chromosomal rearrangements found in hematologic malignancies, including tal-1 d1 found in T-ALL. The product generated by amplification of the ICS using tal-1 d1 -specific primers differs in size from the product generated from the cellular template. By amplifying both the ICS and the genomic tal-1 d1 targets in the same reaction tube, one can control for variables affecting amplification efficiency. Other methods like real-time quantitative PCR (RQ-PCR) utilize fluorogenic probes 25 and are highly sensitive in terms of signal detection, but lack the ability to correct for tube-to-tube reaction efficiency differences (see Ref. 14 for a detailed discussion of this critical issue). A combination of RQ-PCR and ICS-PCR could theoretically combine the advantages of using an internal standard with the speed and sensitivity of real-time analysis.
The amount of genomic DNA and ICS used in each ICS-PCR reaction was maximized in order to have the lowest limits of tumor detection. Typically 3-5 l of blood DNA and 20 molecules of LQ1 were used. When the reaction was complete, the products were separated by gel electrophoresis and stained for 30-60 min using the SybrGold DNA-intercalating dye (Molecular Probes, Eugene, OR, USA). The gel was subsequently scanned with a FluorImager (Molecular Dynamics, Sunnyvale, CA, USA), and the ratio of tumor target to ICS target signals calculated by comparing pixel values using ImageQuaNT software (Molecular Dynamics). For more details, see Hosler et al. 14 In our experience, quantification is best when the ratio of the signals from the translocation and ICS products is close to 1:1. To achieve a 1:1 T:S ratio, if the signal generated using DNA from 3 to 5 l blood was more intense than the ICS band signal, the DNA sample was titrated down in five-fold serial dilutions in separate PCR reactions.
Flow cytometry
Cells were stained with fluorochrome-conjugated antibodies to determine surface phenotype in order to identify a detectable marker for minimal residual disease evaluation in animals. CEM cells were plated at 2.5 × 10 5 cells per well (100 l) in 'V'-bottom 96-well Cell Wells plates (Corning, Corning, NY, USA). The cells were washed with 100 l PBS per well, gently vortexed, re-pelleted, and then resuspended in 100 l PBS. PE-conjugated anti-human-CD5 (Becton Dickinson, San Jose, CA, USA) and FITC-conjugated antimouse-CD5 (PharMingen, San Diego, CA, USA) were added. The cells were incubated on ice for 30 min, pelleted, washed twice with PBS, resuspended in 100 l PBS and filtered through nylon mesh into 1 ml of PBS. Fluorescence data was collected by a FacScan instrument (Becton Dickinson) and analyzed using CELLQuest software (Becton Dickinson).
Leukemia
Chemotherapy
Chemotherapeutic agents were purchased from Sigma (St Louis, MO, USA). Ara-C (cytosine ␤-D-arabinofuranoside free base), doxorubicin (doxorubicin hydrochloride w/lactose), vincristine (sulfate salt), methotrexate ((+) amethopterin), etoposide, and cyclophosphamide (ISOPAC) were used in this study. Ara-C, vincristine, and cyclophosphamide were resuspended in PBS. Doxorubicin was resuspended in saline. Methotrexate and etoposide were resuspended in dimethyl sulfoxide (DMSO) such that the final solution injected contained less than 5% DMSO when diluted in PBS. Concentrations of the stock solutions were 100 mg/ml for Ara-C, cyclophosphamide, methotrexate, and etoposide, and 2 mg/ml for doxorubicin and vincristine. All solutions were stored at −20°C.
Determination of maximum tolerated dose (MTD) in SCID animals
The MTD for different therapeutic reagents was determined by treating healthy female SCID animals (n = 2), 6 to 10 weeks of age. Doses were doubled for each treatment group if the animals survived for 10 days after treatment. Dose escalation was stopped at the first dose that caused Ͼ20% weight loss or death, ie the minimal lethal dose (MLD). The MTD was defined as 50% MLD. The MLDs, administered daily for 4 consecutive days (qd × 4), were 25.6 mg Ara-C, 12.8 mg cyclophosphamide, 0.16 mg doxorubicin, 0.8 mg methotrexate, 4.0 mg etoposide, and 0.04 mg vincristine. Drugs were injected in 200 l of PBS. For therapeutic efficacy experiments, 20% or 50% MTD concentrations were given qd × 4 (n = 5).
Results
Xenograft model development
Engraftment of SCID mice with leukemic cells derived from freshly biopsied material or in vitro established cell lines has been found to mimic human leukemia in many cases, both in terms of disease distribution and prognostic outcome (reviewed in Ref. 23 ). Xenograft models also provide tightly controlled experimental systems to monitor tumor burden during tumor growth in vivo and during therapy. To establish a SCID xenograft model for human T-ALL, it was necessary to identify optimum cell lines, injection routes, and irradiation requirements necessary to give a reproducible engraftment pattern similar to the tissue distribution seen in human T-ALL. A panel of T-ALL cell lines was screened for the tal-1 d1 deletion by PCR for use as a tumor-specific marker. Consistent with previous Southern blot analysis, MOLT-16, CEM, HSB-2, and RPMI 8402 were found to be positive for tal-1 d1 by PCR (data not shown). These lines were injected both i.p. and i.v. (tail vein) into SCID mice previously treated with and without irradiation to determine which combination caused consistent engraftment within a reasonable time frame. Figure 1a shows the survival data following a 10 challenge of SCID mice with graded doses of CEM showed that survival was dose-dependent (Figure 1b) . However, a challenge with 1000 cells or fewer caused no clinical disease, even after extended observation. Whole-body irradiation was not required for engraftment (data not shown).
To investigate the engraftment pattern, animals were injected with 10 7 CEM cells and sacrificed every 7 days. Histologic and PCR analysis of the harvested organs indicated that mice challenged i.v. with CEM developed an engraftment pattern similar to the organ distribution often found in human T-ALL (Figure 1c) . 27 Leukemic-cell infiltration of bone marrow and spleen could be detected by PCR on day 14 after challenge. By day 28 post-tumor challenge, most tissues contained detectable tumor by PCR. Tissue histology of the bone marrow, spleen, and liver from tumor-bearing and non-tumorbearing animals sacrificed on day 28 is shown in Figure 1d .
The SCID/T-ALL bone marrow was hypercellular, with infiltration of a monomorphous population of mononuclear cells. The splenic architecture was completely effaced and replaced with the same cellular infiltrate. In the liver, focal lesions were seen, often proximal to the portal triads. In contrast, i.p. injections of CEM caused local mass lesions without the desired systemic involvement. Therefore, all further experiments were performed using non-irradiated animals injected via the i.v. route.
To investigate whether a leukemic phase was also present in this xenograft model, 11 mice were monitored for disease in the peripheral blood by ICS-PCR (Figure 2 ). Shortly after injection, detectable leukemic cells disappear from the circulation. With time, animals again converted to ICS-PCR-positivity, and the average tumor burden rose exponentially until a plateau phase was reached. On average, tumor was detected Detection and quantification of leukemic phase using ICS-PCR. To determine the presence of a leukemic phase in this model, animals were challenged with 10 7 CEM cells as in Figure 1 . Peripheral blood (10-50 l) was collected from the tail vein after 5 min, 1 h, 1 day, and every 4 to 6 days beginning at day 10. The 5-min and 1-h time-points involved blood collection in the contra-lateral tail vein from the injection site. Sample collection, DNA isolation, and ICS-PCR quantification were performed as described in Methods. The results of ICS-PCR quantification are plotted as the average tumor load (cells/l blood) in the surviving animals vs time. The number of surviving animals is shown for each time-point. The average limit of detection for the assay is indicated.
by PCR more than 1 week before clinical disease onset and more than 2 weeks before death. In over 100 mice analyzed, only one animal has died from CEM without evidence of disease by ICS-PCR in blood. Interestingly, this exception showed behavioral changes suggesting that CNS infiltration had occurred before extensive blood-born disease.
Animals challenged with CEM i.v. had reproducible disease, a dose-dependent survival pattern with 10 7 cells causing 100% lethality, and the desired engraftment pattern resembling human T-ALL. The presence of a leukemic phase and a detectable tumor-specific molecular marker (tal-1 d1 ) allows for the monitoring of tumor growth using ICS-PCR as a tumordetection method.
Comparison of ICS-PCR and flow cytometry for T-ALL detection and quantification
Flow cytometry is commonly used to diagnose leukemia based on the expression of specific cell-surface markers, and can also be used to detect minimal residual disease. Flow cytometry was compared with ICS-PCR in terms of limits of detection and ability to predict disease onset. Peripheral blood of 35 mice was analyzed every 4 to 6 days beginning on day 15 post i.v. challenge using both detection methods, and representative samples are shown (Figure 3) . At day 21, 30 of 35 (seven of nine shown) blood samples gave detectable tal-1 d1 products by PCR (Figure 3a top) ; in some cases, strong product bands were observed (eg Nos 3 and 7), some samples gave weak product bands (eg Nos 4 and 6), and some samples were negative (eg Nos 8 and 10). The same samples were analyzed by flow cytometry using a human-specific anti-CD5 antibody and a murine anti-CD5 control such that T-ALL cells appear in the upper-left quadrants of the flow diagrams (Figure 3a bottom). All samples that were PCR strong-positive were also Leukemia detectable by flow. However, T-ALL cells were not detected by flow in many of the samples in the PCR weak-positive group.
In 132 non-control samples covering the entire experiment from days 15 to 98, 55 were positive by both techniques, 64 were negative by both techniques, 12 were positive by ICS-PCR and negative by flow, and one was negative by ICS-PCR and positive by flow (Figure 3b) , for a concordance rate of 90.1% (119/132). Of the 12 samples that were ICS-PCRpositive/flow-negative, blood samples from these mice all became flow-positive within the next two time-points (10 days), suggesting that they were real positives. For the one example that was flow-positive/ICS-PCR-negative, the animal did not convert to ICS-PCR-or flow-positive nor did the animal get sick, suggesting that this was a false positive. Thus, the ICS-PCR assay provides lower limits of detection than flow cytometry in this system.
To compare quantification by the two assays, tumor fractions determined by each assay were compared in all the samples positive by both techniques (Figure 3c ). Quantification of tumor fraction by the two techniques was similar. As a result, the points cluster around a best-fit curve with a slope = 0.9 and the y-intercept = 0.1, indicating minimal proportional or constant error when comparing the two techniques. The R 2 value of 0.81 is indicative of some random error between the two techniques, but it is unclear how much of this is attributable to the flow or ICS-PCR assays.
In these experiments, ICS-PCR had a lower limit of detection than flow cytometry by 2-5-fold (not shown). The ICS-PCR method provided an average of 13 days between tumor detection and death, compared with 11 days by the flow assay, and 4 days by clinical examination alone (not shown).
Initial therapeutic response as a surrogate marker of survival
Response to initial therapy is a potential surrogate marker for survival. ICS-PCR can be used to objectively quantify a therapeutic response. Animals challenged with CEM were treated with individual chemotherapeutic agents at 20% or 50% the MTD on days 21 to 24 post-tumor challenge (qd × 4) and were followed for survival. Survival curves for the most effective dose of each single therapeutic agent (Figure 4a) show that Ara-C, cyclophosphamide, and vincristine were highly effective in increasing survival, etoposide had a moderate effect, and doxorubicin and methotrexate had little or no effect. Animals were also monitored by ICS-PCR to determine tumor load. Mice were bled pre-and post-therapy and every 4 to 6 days following treatment. Doxorubicin had no effect on tumor load as compared to the untreated controls (Figure 4b ). Vincristine had a moderate effect, reducing the tumor load several logs before a rapid rebound in tumor expansion (Figure 4c) . Ara-C treatment significantly reduced tumor load from day 21 to day 27, with three of five mice maintaining undetectable levels for over 1 week (Figure 4d) .
The therapeutic responses to various doses of each chemotherapeutic agent and the correlation to disease-free interval are shown in Table 1 . In virtually all cases, animal survival was directly related to tumor reduction. For example, treatment with Ara-C at 50% MTD gave the highest reduction in tumor load in the 6-day period (3 logs) and extended survival the longest (25 days). The only exception was the 50% MTD etoposide treatment group. These animals showed effective tumor clearance yet short survival. In this case, toxic syner- gism between drug treatment and tumor effects may explain the rapid decline in health of these animals.
In addition to the quantitative therapeutic response, the final MRD level following induction therapy was also found to correlate with survival (Table 2) . Animals with lower levels of tumor at day 27 post-tumor challenge, for example Ͻ50 tumor cells/l blood (vincristine, cyclophosphamide, and Ara-C treatment groups), had a significantly longer disease-free interval than those with higher MRD (PBS, doxorubicin, and methotrexate treatment groups). Again, the only exception is the 50% etoposide group, which effectively reduced tumor load without extending survival.
The strong correlation between quantitative therapeutic response and MRD levels and survival was also observed on an individual animal basis, regardless of the therapeutic agent used ( Figure 5 ). Again, animals with the highest rate of tumor reduction (Figure 5a ) or the lowest level of MRD following therapy (Figure 5b ) demonstrated the longest disease-free interval.
Discussion
The detection and quantification of tumor load in the peripheral blood of subjects with leukemia can be added to the list of surrogate markers for survival. In this murine model of human T-ALL, the expanding population of leukemic cells carrying the tal-1 d1 deletion was monitored by quantitative ICS-PCR and shown to predict disease onset. Perhaps more importantly, we have also shown that the initial quantitative therapeutic response is a surrogate marker of survival. This response can be assessed by the dynamic rate of tumor reduction following initial therapy or by quantified level of MRD at specific time-points after therapy. Both parameters strongly correlated with disease-free interval.
Several groups are presently studying the prognostic significance of tumor response to induction therapy using flow cytometry and PCR-based assays. The consensus appears to be that a good initial response to therapy and undetectable MRD following remission-induction highly correlates with a favorable patient outcome. 9, 13, [28] [29] [30] [31] For example, Dibenedetto et al 30 looked at the significance of MRD detection by heminested PCR in bone marrow at the beginning of maintenance therapy in 17 patients with T-ALL. They showed that all of the patients without detectable MRD at the onset of maintenance therapy had an event-free survival beyond 5 years, and none of the patients with detectable MRD were event-free at 5 years. However, in some PCR-based studies using very sensitive assays, PCR-positivity did not predict outcome. [32] [33] [34] The reasons that low levels of detectable MRD were not associated with relapse under these circumstances remain unclear, but may relate to the presence of residual tumor-specific DNA not associated with viable cells, pre-leukemic cells, or a tumor dormancy effect. Other groups have shown that while simple detection of MRD is useful in predicting outcome, the levels of MRD are better prognostic indicators. 11, 12 Cave et al 12 found that although MRD detection was predictive of relapse at all timepoints during therapy of ALL patients, the level of MRD more strongly predicted outcome. For example, at the end of induction therapy, the relative risk of relapse for patients with detectable MRD was 5.7, but the relative risk for those with more than one leukemic cell per 100 normal cells was 16.0. Likewise, after consolidation therapy, the relative risk for those with detectable MRD was 7.3 and those with more than one leukemic cell per 1000 normal cells was 15.3. Taken together, these studies support the idea that MRD detection and quantification during therapy are potential surrogate markers for patient outcome. Because the significance of MRD data varies depending on the disease and the assays used, the continuation of these types of studies is critical to rectify some of the apparently discrepant preliminary findings. The low limits of PCR detection and its relative ease of use Leukemia makes this assay attractive for these types of studies. Additionally, with growing evidence that MRD levels are superior for predicting outcome rather than simple detection, quantitative PCR approaches may begin replacing other methods. The findings that the quantitative tumor response to induction therapy is predictive of survival are especially attractive because it would provide prognostic information within the first months of therapy. Identifying high-risk patients at this stage, before histological or clinical relapse, is likely to improve survival since these patients can be approached aggressively before the development of resistant disease. Thus, these early surrogate markers of survival promise to improve patient outcome by guiding risk-directed therapeutic approaches.
SCID xenograft models and quantitative detection assays appear to be excellent systems for the evaluation of therapeutic efficacy in vivo. 18, 19, 21, 22 In vitro assays cannot evaluate complex properties of treatment protocols such as toxicity and efficacy of multi-agent regimens, scheduling, and in vivo development of resistance. Some groups have shown that some human cells change their surface phenotype, differentiate or mature, and, at times, behave differently in relation to drug resistance when placed in vivo. 27, 35 Additionally, since xenograft models use human tumors, drug sensitivity and resistance information may more accurately reflect tumor responses in human patients. Because ICS-PCR can accurately quantify tumor response to therapy, it can be used to evaluate multi-agent therapy, toxicity profiles, scheduling, and novel therapies on human tumors without using survival as an end point.
In addition to the identification of surrogate markers for therapeutic efficacy and survival, the results from these ICS-
Figure 5
Initial therapeutic response correlates with animal survival. Data for each individual animal from the experiment described in Figure 4 was plotted to analyze the correlation between (a) the rate of tumor response following therapy and survival and (b) MRD levels following therapy and survival. Tumor levels were quantified using ICS-PCR. The rate of tumor reduction was calculated as (log[tumor cells/l blood] from day 21) − (log[tumor cells/l blood] from day 27). MRD levels were determined at day 27. These calculations evaluate the tumor response to therapy given on days 21 to 24. Linear regression analysis was used to draw a best-fit line for both plots. The dashed line in (b) represents the average limit of detection for ICS-PCR in this experiment; points on this line represent undetectable tumor in the respective murine blood sample.
PCR experiments on the response of this T-ALL graft to chemoreagents have other therapeutic implications. Ara-C, cyclophosphamide, and vincristine were all effective at reducing tumor levels. Doxorubicin, methotrexate, and etoposide were not as effective. Doxorubicin, an agent used in current pediatric T-ALL treatment protocols, was ineffective at reducing tumor load in this animal model, while cyclophosphamide, an agent omitted from current protocols, rapidly reduced tumor burden. Similar sensitivity profiles were obtained in mice challenged with another T-ALL cell line, HSB-2 (data not shown). Whether these responses are a general property of T-ALL, are tumor-specific, or relate to the use of in vitro established cell lines is currently under investigation. The relative resistance of CEM to doxorubicin may be related to the p53 genotype of this line. p53 mutations have been found in up to 50% of T-ALL cell lines 36 and up to 70% of T-ALL patients in relapse, 37 possibly contributing to resistance to DNA-damaging chemotherapeutic agents during relapse. CEM has been shown to carry heterozygous p53 point mutations. 36 Through transfection experiments with wild-type p53, CEM has been shown to gain sensitivity to doxorubicin in vitro. 38 It is possible, therefore, that CEM does not respond well to certain agents (eg doxorubicin) in vivo because of an underlying p53 mutation. However, the fact that CEM is sensitive to ara-C and cyclophosphamide in vivo suggests that these drugs are able to kill cells through p53-independent mechanisms. Regardless of the explanation, this data suggests that this type of SCID/human xenograft model along with the use of ICS-PCR analysis of tumor burden may be an effective method for evaluating and optimizing therapeutic protocols in general, or even at the level of the individual tumor.
